MedTrace Logo

Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients

NCT06463691 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-11

No results posted yet for this study

Summary

This is a an open-label, multi-center, single-arm study to evaluate the efficacy and safety of sonrotoclax, zanubrutinib and CD20mab in untreated MCL patients.

Conditions

Interventions

DRUG

BGB-11417

Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule

DRUG

BGB-3111

Zanubrutinib, orally, 320 mg total daily dose

DRUG

CD20

CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-01
Primary Completion
2028-12-31
Completion
2029-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06463691 on ClinicalTrials.gov